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Recombinant Filaggrin Is Internalized and Processed
to Correct Filaggrin Deficiency
Thomas E. Stout1, Trevor McFarland1, John C. Mitchell2, Binoy Appukuttan1 and J. Timothy Stout1
This study was designed to engineer a functional filaggrin (FLG) monomer linked to a cell-penetrating
peptide (RMR) and to test the ability of this peptide to penetrate epidermal tissue as a therapeutic strategy for
genetically determined atopic dermatitis (AD). A single repeat of the murine filaggrin gene (Flg) was covalently
linked to a RMR motif and cloned into a bacterial expression system for protein production. Purified FLGþRMR
(mFLGþRMR) was applied in vitro to HEK-293T cells and a reconstructed human epidermis (RHE) tissue model.
Immunochemistry demonstrated RMR-dependent cellular uptake of FLGþRMR in a dose- and time-dependent
manner in HEK cells. Immunohistochemical staining of the RHE model identified penetration of FLGþRMR to the
stratum granulosum, the epidermal layer at which FLG deficiency is thought to be pathologically relevant. In vivo
application of FLGþRMR to FLG-deficient flaky tail (ft /ft) mice skin demonstrated internalization and processing
of recombinant FLGþRMR to restore the normal phenotype. These results suggest that topically applied RMR-
linked FLG monomers are able to penetrate epidermal tissue, be internalized into the appropriate cell type, and
be processed to a size similar to wild-type functional barrier peptides to restore necessary barrier function, and
prove to be therapeutic for patients with AD.
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INTRODUCTION
Ichthyosis vulgaris (IV) is the most common disorder of
keratinization, with an incidence of 1 in 250 in western
countries (Wells and Kerr, 1966; Brown et al., 2008). It is
a monogenetic, autosomal semidominant disease displaying
variable penetrance, and is typically characterized by
hyperlinearity of the palms and soles, dry flaky skin, pruritis,
and keratosis pilaris (Manabe et al., 1991; DiGiovanni, 2003;
Judge et al., 2004). Histopathologically, IV is characterized by
an attenuated granular layer and abnormal or absent
keratohyalin granules (Sybert et al., 1985). A defect in the
barrier function of the epidermis is the physiological hallmark
of IV, and thus it is associated with an increased entry of
allergens, antigens, and chemicals into the skin (Candi et al.,
2005; McLean, 2011).
Although a reduction in the protein filaggrin (FLG) was
noted in skin biopsies of patients with IV (Sybert et al.,1985;
Fleckman et al., 1987), it was not until 2006, when two loss-
of-function mutations were discovered in the first repeat of
exon 3 of the FLG gene (R501X and 2282del4), that a genetic
basis for IV was elucidated (Smith et al., 2006). A variety of
mutations within FLG have been associated with IV, and
common allele frequencies have since been determined in
European, North American, and Asian populations (Reuther
et al., 2006; Weidinger et al., 2006; Barker et al., 2007;
Nomura et al., 2007; Chen et al., 2011).
Although FLG is a large three-exon gene, only exon 3 is
protein encoding (Presland et al., 1992). Exon 3 is exceptionally
large at 12,753 bp and comprises 10–12 virtually identical
972-bp tandem repeats (Gan et al., 1990). The murine FLG
gene is similar in structure, but exon 3 comprises 20 repeats
ranging from 750 to 765 bp (Rothnagel and Steinhert, 1990).
A spontaneous frameshift mutation (5303delA) in the mouse Flg
gene (ft /ft) results in a deficiency of epidermal FLG and a
phenotype similar to humans with IV (the ‘‘flaky tail’’ mouse,
Presland et al., 2000; Fallon et al., 2009).
After translation, the FLG protein is normally despho-
sphorylated and proteolytically processed into functional
FLG monomers by endoproteases including caspase 14
(Denecker et al., 2007). As keratinocytes migrate through
the granular and corneal layers of the epidermis, FLG
monomers associate with keratin intermediate filaments
to aggregate into tight bundles (Manabe et al., 1991).
Aggregation of keratins promotes the collapse of
keratinocytes into flattened corneocytes that are associated
with the mature cornified envelope. Monomeric FLG is
cleaved during epidermal proliferation to release amino
acids that contribute to ‘‘natural moisturizing factors’’
necessary for epidermal hydration and barrier function
(Rawlings and Harding, 2004). Patients with decreased FLG
protein exhibit increased transepidermal water loss and
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perturbed epidermal barrier function (Kezic et al., 2008;
O’Regan et al., 2010; Angelova-Fischer et al., 2011). Null
mutations for FLG have been identified as key factors
associated with the ‘‘atopic march’’—the temporal pro-
gression of IV to atopic dermatitis (AD) and other atopic
diseases including food allergies, asthma, and allergic rhinitis
(Spergel, 2010; Brown et al., 2011; Hogan et al., 2012).
Development of a therapy aimed to treat the genetic defects
associated with IV and these other diseases is warranted.
We describe an approach for the treatment of AD via the
topical introduction of recombinant FLG monomer protein
covalently linked to the human immunodeficiency virus trans-
activator of transcription–derived cell-penetrating peptide
(RMR) protein motif (henceforth termed mFLGþRMR). We
demonstrate the ability of recombinant FLG to (a) be inter-
nalized by cells in vitro in an RMR-dependent manner,
(b) penetrate a human epidermal tissue model to the patho-
logically relevant layers, (c) be internalized by dermal cells
and appropriately processed after topical delivery to a flaky
tail mouse model, and (d) restore the normal phenotype in this
animal model. These results suggest that topically delivered
recombinant FLG can be an effective therapy for AD. The
application of this delivery system to other epidermal peptides
may be used to treat other epidermal diseases involving
protein deficiency.
RESULTS AND DISCUSSION
We used in vitro and in vivo models to test the ability of
recombinant monomeric FLG to (a) penetrate epidermal tissue
after topical application, (b) be internalized by the appropriate
cell type, (c) be processed to an appropriate size, and (d)
restore the murine phenotype associated with FLG deficiency.
In vitro application of mFLGþRMR and mFLG-RMR to
HEK-293T cells demonstrated dose- and time-dependent
cellular internalization of FLG. Immunocytochemistry (ICC)
specific to the Trx epitope of mFLGþRMR demonstrated
cellular internalization after application of 8mg of mFLGþ
RMR (Figure 1). Cellular internalization increased after
increasing the dose to 80mg. ICC demonstrated time-depen-
dent internalization of mFLGþRMR, as intracellular
staining increased after incubation time was lengthened
from 1 to 4.5 hours (Figure 1). Cellular internalization of
mFLGþRMR in HEK-293T cells was RMR dependent.
Although mFLGþRMR readily penetrated the cell membrane,
mFLG-RMR was unable to do so. These results suggest that the
RMR motif is required for cellular internalization of recombi-
nant FLG.
As ICC performed on HEK cells was specific to the Trx
epitope of the recombinant FLG, an additional monomer
lacking the Trx tag (mFLGþRMR-Trx) was applied to human
dermal fibroblasts (HDFs) along with mFLG-RMR. ICC was
performed using FLG antibodies and, as consistent with the
HEK data, only RMR-linked FLG was internalized by the cells
(Figure 2a). To investigate the specific cellular localization of
recombinant FLG, HDFs treated with mFLGþRMR-Trx and
mFLG-RMR were separated into cytoplasmic, membrane-
bound, and nuclear protein fractions. Immunoblots of each
fraction were probed with FLG antibodies to determine uptake
and subcellular location of recombinant FLG. Although
western blot analysis of HDFs treated with mFLGþRMR-Trx
demonstrated abundant transprotein in the cytoplasmic frac-
tion, cells treated with mFLG-RMR evidenced no transprotein
uptake (Figure 2b, c). These data, in conjunction with the ICC
images, indicate that RMR-linked FLG is able to penetrate
both HEK and HDF cells and localize in the cytoplasm.
Tandem mass spectrometry of marker proteins was used to
confirm adequate subcellular fractionation (Figure 2d).
Application of mFLGþRMR to the reconstructed human
epidermis (RHE) tissue model demonstrated the ability of
recombinant FLG to temporally penetrate the epidermis to
pathologically relevant layers. When 50mg of mFLGþRMR
was applied to the RHE for 15 minutes, staining specific for
recombinant FLG was limited to the corneal layer. After
60 minutes, mFLGþRMR had penetrated to the stratums
lucidum and granulosum, and after 240 minutes the recombi-
nant FLG had migrated to the granular and basal layers
(Figure 3). One important role of FLG is to contribute to
epidermal barrier function by promoting keratin filament
aggregation in the basal and granular layers (Sybert et al.,
1985). Evidence demonstrating that topically applied FLG can
penetrate a human tissue model to these layers supports the
use of recombinant RMR-linked FLG to treat FLG deficiency.
Recombinant FLG was applied to flaky tail mice to test for
cellular internalization, intracellular processing, and phenoty-
pic rescue. Immunohistochemistry (IHC) performed on tissue
collected from mature flaky tail mice after a 1-hour
8 μg mFLG-RMR
1.5 hours
8 μg mFLG+RMR
1.5 hours
80 μg mFLG+RMR
1.5 hours
80 μg mFLG+RMR
4.5 hours
Figure 1. Immunocytochemistry of HEK-293Ts after filaggrin (FLG) application. Immunocytochemistry using a Trx probe after an application of 8mg of mFLG-
RMR for 1.5 hours, 8mg of mFLGþRMR for 1.5 hours, 80mg of mFLGþRMR for 1.5 hours, or 80mg of mFLGþRMR for 4.5 hours. Protein concentration was
0.4mgml 1. Bar¼50mm.
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application of 50mg of mFLGþRMR exhibited a staining
pattern similar to native C57 mouse tissue (Figure 4). Recom-
binant FLG was present in the stratum corneum of treated
flaky tail mice, the layer of epidermis where FLG contributes
to the natural moisturizing factors that are key for skin
hydration and epidermal barrier function.
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Figure 2. Immunocytochemistry (ICC) and western blots of human dermal fibroblasts (HDFs). (a) ICC using filaggrin (red) and cytoskeletal phalloidin (green)
antibodies after an application of 5mg of mFLGþRMR-Trx for 4 hours, 5mg of mFLG-RMR for 4 hours, or medium only for 4 hours. Protein concentration was
0.04mgml1. Bar¼ 50mm. Western blot using a FLG probe against HDF cells treated with 20mg of either (b) mFLGþRMR-Trx or (c) mFLG-RMR for 4 hours.
Applied filaggrin (red arrow) and b-actin (black arrow) are highlighted. Protein concentration was 0.01mgml1. (d) Tandem MS/MS spectral analysis of three
subcellular marker proteins: fatty acid synthase (cytoplasmic), Naþ /Kþ ATPase subunit alpha-1 (membrane), and poly(ADP-ribose) polymerase (nuclear).
50 μg mFLG+RMR
15 minutes
50 μg mFLG+RMR
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50 μg mFLG+RMR
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10 μm 50 μm 50 μm
Figure 3. Immunofluorescence of reconstructed human epidermis (RHE) after recombinant filaggrin application. Immunohistochemistry using a mouse-specific
filaggrin probe after an application of 50mg of mFLGþRMR for 15 minutes, 50mg of mFLGþRMR for 60 minutes, or 50mg of mFLGþRMR for 240 minutes.
Protein concentration was 0.5mgml 1. Bar¼50mm.
a b c
Figure 4. Immunofluorescence of flaky tail and C57/BL6 dorsal skin. Immunohistochemistry using filaggrin (FLG) antibodies against (a) adult flaky tail mice
treated with 50mg of mFLGþRMR (0.5mgml 1), (b) adult flaky tail mice treated with a vehicle solution only, or (c) untreated adult C57/BL6 mice. Bar¼100mm.
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Western blot analysis of tissue collected from mature flaky
tail mice was performed to investigate cellular internalization
and processing after topical recombinant FLG administration.
Although the 50-kDa mFLGþRMRþ Trxþpolyhistidine pro-
tein was detected, a 28-kDa protein corresponding to nor-
mally processed FLG monomers was also present, suggesting
that intracellular processing of the input protein resulted
in biologically relevant monomers (Figure 5). Although the
larger input protein was observed in the tissues of animals
treated with mFLG-RMR (possibly due to the inherent barrier
dysfunction of the flaky tail model), the 28-kDa monomeric
FLG was absent from these animals, suggesting that the RMR
motif is needed for efficient cellular internalization and
processing.
To test the ability of mFLGþRMR to restore normal
phenotype in flaky tail mice, either 50mg of mFLGþRMR
(0.5mgml1) or the delivery vehicle alone was applied
to flaky tail littermates daily for 14 days (p5–p19). Immuno-
histochemistry performed on treated neonatal mice showed
similar results to those of adult flaky tail mice that received
treatment for 1 hour: staining of FLG was present in the
stratum corneum of treated flaky tail mice, and the
staining pattern for treated animals resembled that of native
C57 tissue (Figure 6a–c). Flaky tail mouse controls evidenced
negligible staining for FLG. Hemotoxylin and eosin staining
of untreated flaky tail tissue showed a markedly attenuated
stratum corneum when compared with treated animals
(Figure 6d, e). As FLG breakdown products are major
constituents of the corneal layer, these results suggest that
topically applied FLG monomer is processed appropriately in
flaky tail mice, which may promote the formation of a
functional cornified envelope.
Environmental-scanning electron microscopy of treated p18
flaky tail mice showed a reversal of the disease phenotype to a
normal appearance. A more uniform scale formation and an
overall smoother surface was seen in treated animals when
compared with untreated littermates (Figure 6f–i). Although
scale formation appeared to be consistent throughout the
length of the tail in treated mice, the skin of untreated animals
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mFLG-
RMR
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only None
mFLG+
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Figure 5. Western blot of mouse tissue. Western blot of adult flaky tail dorsal
tissue treated with 50mg of mFLGþRMR (0.5mgml 1, 1 hour), adult flaky tail
dorsal tissue treated with 50mg of mFLG-RMR (0.5mgml 1, 1 hour), adult flaky
tail dorsal tissue treated with a vehicle solution only (1 hour), untreated
C57/BL6 mice, pure mFLGþRMR protein, or pure mFLG-RMR protein. Wild-
type filaggrin monomer (red arrow) and processed monomeric recombinant
filaggrin (black arrow) are highlighted.
a d f
g
h
ie
b
c
Figure 6. Immunohistochemistry, histology, and electron microscopy of mouse tail epidermis. (a–c) Immunohistochemistry, (d, e) hematoxylin and eosin staining,
and (f–i) environmental-scanning electron microscopy (E-SEM) of (a, d, f, h) p18 flaky tail mice treated with 50mg of mFLGþRMR (0.5mgml1) daily for 14 days,
(b, e, g, i) p18 flaky tail mice treated with a vehicle solution daily for 14 days, or (c) p18 untreated C57/BL6 mice.
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exhibited numerous rhytides because of epidermal scales of
varying sizes. In addition, the scales of treated mice were well
attached at their articulation points, whereas those of
untreated mice lifted off of the surface. These results are
consistent with the physiological differences seen between
healthy patients and those with IV, indicating that topical
application of recombinant FLG may be able to restore the
normal phenotype in patients with this disease. The flaky tail
mice used in this study were double mutants, concurrently
expressing a matted-hair phenotype (ma/ma) along with the
FLG mutation. It is possible that such a double mutation could
permit the internalization of recombinant FLG to a greater
degree than might be observed in FLG-deficient animals that
lacked the matted-hair genotype.
We have shown that recombinant FLG, when fused to an
RMR cell-penetrating peptide motif, can be internalized and
processed in epidermal cells to restore the normal phenotype
in the flaky tail mouse model. In vitro tests demonstrated
RMR-mediated tissue penetration and cellular uptake of FLG
in a dose- and time-dependent manner. Given the ability of
the cell-penetrating peptide motif of the HIV-derived trans-
activator of transcription protein to drive cellular internaliza-
tion, we hypothesized and have demonstrated that similar
cell-importation motifs can be used to deliver functional
proteins percutaneously for the potential treatment of AD.
Although alternative protein delivery methods exist (liposo-
mal, viral, and so on), we feel that the flexibility inherent in
direct protein delivery to treat other disorders resulting in
protein deficiency has strong therapeutic potential.
The therapeutic ability of topically applied recombinant
FLG has broad implications. As the atopic march has been
established as a presage to numerous atopic diseases, an
ability to alter this process may prove to be therapeutic for
diseases more common than IV. AD has been established as
the progenitor for several atopic disorders. Thirty to fifty
percent of children with AD develop asthma, and two-thirds
develop allergic rhinitis (Spergel, 2010). AD has also been
associated with an increased likelihood of dust mite (Marsella
and Samuelson, 2009) and alternaria allergies (Hedayati et al.,
2009). The fact that up to 56% of patients with AD have FLG-
null alleles (Irvine, 2007) highlights the role FLG-associated
skin barrier dysfunction has in the advancement of allergic
diseases and the importance of identifying and correcting the
genetic factors that drive such diseases.
MATERIALS AND METHODS
Mice
Flaky tail (ft /ft, ma/ma) mice were purchased from the Jackson
Laboratory (Bar Harbor, ME) and C57/BL6 mice were purchased
from Charles River Laboratories (Wilmington, MA) and were treated
in accordance with IACUC and OHSU Department of Comparative
Medicine guidelines.
Cell culture
HEK-293T cells and HDFs (ATCC, Manassas, VA) were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) (Life Technologies,
Carlsbad, CA) and human fibroblast basal medium (ATCC), respec-
tively, and were tested when cells had reached 75% confluency.
EpiDerm (MatTek, Ashland, MA) RHE inserts were transferred to six-
well culture plates containing 3.0 ml of fresh EPI-100-LLMMM-X
medium/well upon arrival and were placed in a 37 1C incubator with
5% CO2 for 18 hours before experimentation.
Recombinant FLG production
Two proteins containing a single FLG monomeric repeat were
produced using the BacPower Bacterial Expression System
(GenScript, Piscataway, NJ): mouse FLG with and without the RMR
motif (mFLGþRMR and mFLG-RMR, respectively). This expression
system included gene synthesis and subcloning into a pUC57 E. coli
expression vector, 1L expression, and one-step affinity column
purification. The storage buffer for both peptides was made up of
50 mM Tris-HCl, 300 mM NaCl, pH 8.5.
mFLGþRMR-Trx was produced using the NovoProtein E. coli
Expression System (Novoprotein, Summit, NJ). This included gene
synthesis and subcloning into a pCOLDII E. coli expression vector, 2 l
expression, and Ni Chelating affinity column purification. The storage
buffer was made up of 20 mM Tris, 500 mM NaCl, 1 mM EDTA, and
0.5 mM PMSF, pH 8.5. The concentration and purity for each peptide
were as follows: mFLGþRMR—0.801 mg ml 1 and 470%; mFLG-
RMR—1.12 mg ml 1 and 470%; mFLGþRMR-Trx—0.38 mg ml 1
and 485%.
The RMR motif was derived from the human immunodeficiency
virus trans-activator of transcription protein and consisted of 10 Arg
and Met residues covalently linked to the C terminus of the FLG
peptide. Several studies have described trans-activator of transcription–
derived cell-penetrating motifs to permit efficient internalization when
fused to the C terminus of proteins (Li et al., 2002; Shokolenko et al.,
2005). As extensive FLG processing occurs during cornification, the
peptides were designed to include the flanking junctional sequences of
the adjacent FLG repeats and the associated cleavage sights necessary
for such processing (Figure 7). The sequence for the peptides used in
this study can be found in Supplementary Figure S1 online.
Western blot analysis
Tissues collected for western blotting were homogenized, proteins
were electrophoresed through SDS-PAGE gels, and were transferred
to nitrocellulose by standard techniques. Blots were probed with
polyclonal antibodies directed against FLG (PRB-417P, Covance,
Princeton, NJ) and developed using a LI-COR ODYSSEY Infrared
Imaging System (LI-COR Biosciences, Lincoln, NE), according to the
manufacturer’s recommendations.
Exon 1
(50 bp)
5′-UTR
Exon 2
(159 bp)
Exon 3 (20,750 bp filaggrin
repeats)
3′-UTR
Trx His FLG RMR
Figure 7. Profilaggrin schematic and recombinant mFLGþRMR protein
sequence. (a) Schematic of murine profilaggrin with isolated filaggrin monomer
linked to 50-RMR tag. (b) Corresponding sequence of filaggrin (FLG) þRMR
recombinant protein. Red, purple, blue, orange, and green amino acids denote
the Trx tag, polyhistidine tag, filaggrin monomer, flanking junctional filaggrin
sequences, and RMR motif, respectively. UTR, untranslated region.
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Environmental-scanning electron microscopy
Tissue collected for environmental-scanning electron microscopy was
fixed in 2% glutaraldehyde in distilled water for 36 hours and fully
hydrated in a graded PBS series (50, 40, 30, and 20%). The samples
were fixed on SEM stubs and photographed using an FEI Quanta
environmental-scanning electron microscope (FEI, Hillsboro, OR)
with 5.00 kV accelerating voltage using a low vacuum mode and a
large field detector.
Mass spectrometry
To identify proteins in the cytoplasmic, nuclear, and membrane
fractions, 30mg of each was dried and resuspended in 5ml of Novex
(Life Technologies) NuPage LDS sample buffer (4 ), 1ml of Novex
reducing agent (20 ), and 14ml of water. Samples were electro-
phoresed through a Bis-Tris gel and visualized with Imperial Blue
stain (Thermo Fisher, San Jose, CA). In-gel tryptic digestion was
performed according to Shevchenko et al. (2007). Extracted
peptides were filtered, dried, and resuspended in 5% formic acid.
LC MS and MS/MS spectra were obtained on an LTQ Velos linear ion
trap mass spectrometer (Thermo Fisher) with 10ml of each sample
applied to a C18 trap cartridge and then chromatographed on a
0.5 250 mm2 5-mm particle-size Zorbax SB-C18 column using
mobile phase containing 0.1% formic acid and 7–30% acetonitrile
over 65 minutes. Data were searched against the Swiss-Prot human
database and processed using in-house python scripts (Wilmarth et al.
2009). SEQUEST (version 28, Thermo Fisher) searches were
performed with trypsin specificity, average parent ion mass
tolerance, 2.5 Da, average fragment ion mass tolerance, 1.0 Da,
static modification of þ 57 Da on all cysteine residues, and
variable modification of þ 16 Da on methionine. The SQT files
(McDonald et al. 2004) were imported into Scaffold
(Proteome Software, Portland, OR) with settings of Min Protein
99%, Min # Peptide¼ 2, and Min Peptide 99%. Mass spectrometric
analysis was performed by the OHSU Proteomics Shared Resource
with partial support from NIH core Grants P30EY010572 and
P30CA069533.
Immunolabeling
Chamber slides containing HEK-293T or HDFs at 75% confluency
were fixed in acetone, whereas RHE and mouse tissues were fixed in
10% neutral-buffered formalin for 18 hours, embedded in paraffin,
and sectioned (8mm). HEK-293Ts were stained with polyclonal
antibodies directed against the Trx motif on mFLGþRMR and
mFLG-RMR (ab26320, Abcam, Cambridge, MA) followed by an
anti-rabbit secondary antibody (A21206, Life Technologies) for
detection. HDFs were stained with polyclonal FLG antibodies
(PRB-417P, Covance) followed by an anti-rabbit secondary antibody
(A10042, Life Technologies), 40,6-diamidino-2-phenylindole, and a
cytoskeletal phalloidin marker (A22287, Life Technologies) for
detection. RHE inserts and mouse tissues were stained with
polyclonal FLG antibodies (for RHE: M-290, Santa Cruz Biotechnol-
ogy, Santa Cruz, CA; for mouse tissue: PRB-417P, Covance)
followed by an anti-rabbit secondary antibody (A10042, Life Tech-
nologies) and 40,6-diamidino-2-phenylindole for detection.
Images were taken using an Olympus FluoView FV1000 confocal
microscope (Olympus, Tokyo, Japan). For all experiments, controls
in the absence of primary antibody showed no reaction with the
sample.
In vitro protein applications
Either 8 or 80mg of mFLGþRMR or mFLG-RMR was applied to HEK-
293T cells at a concentration of 0.4mgml 1 for 1 or 4.5 hours. Cells
were washed with PBS before collect ing protein. For HDFs, 20mg
(0.04mgml 1 in medium) of either mFLGþRMR-Trx or mFLG-RMR
was applied for ICC and 5mg (0.01mgml 1 in medium) of either
mFLGþRMR-Trx or mFLG-RMR was applied for immunoblotting. All
protein applications to HDFs were for 4 hours. For subcellular
fractionation analysis and subsequent gel electrophoresis, the
media–protein mixture was collected and the cells were washed
three times with PBS. The cell mixture was subsequently fractionated
into cytoplasmic, membrane-bound, and nuclear fractions using the
Subcellular Protein Fractionation Kit (Thermo Fisher). For RHE, either
50mg of mFLGþRMR in a 50% EtOH vehicle solution (0.5mgml 1)
or 200ml of vehicle-only solution was applied to the apical surface of
the RHEs for 15, 60, or 240 minutes.
In vivo protein applications
For in vivo studies, 50mg of either mFLGþRMR or mFLG-RMR was
applied at a concentration of 0.5mgml 1 in a 50% EtOH vehicle to
shaved dorsal sections of mature flaky tail mice for 1 hour. EtOH
vehicle solution without protein was applied as a control. Another
cohort of animals received applications of either 50mg of mFLGþRMR
in the vehicle solution (0.5mgml 1) or vehicle-only solution, daily for
14 days (p5–p18). Following these applications, sites of delivery were
washed with PBS to eliminate surface protein. Tissue was also
collected from mature and p18 untreated C57/BL6 control mice.
Hemotoxylin and eosin staining was performed on collected tissues.
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